Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAT-2645 in Advanced Solid Tumors with BRCA1/2 or DDR Defects
NCT06614751Phase 1Not yet recruiting
- Sponsor
- Danatlas Pharmaceutical Inc.
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DAT-2645 in solid tumor (advanced stage), breast cancer, prostate cancer (PCa) and 4 more, sponsored by Danatlas Pharmaceutical Inc. Primary endpoints: Number of participants with dose limiting toxicities, adverse events, and laboratory abnormalities at 6 months and Overall Response Rate at 2 years. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
DAT-2645
03
Conditions
solid tumor (advanced stage)breast cancerprostate cancer (PCa)colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06614751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06614751.